Drugs / Xentuzumab
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05110495 | Dec 2021 → Mar 2023 | prostate cancer | University of Oxford | Completed | No outcome recorded |
| Phase 17 trials · 2 missed | ||||||
| Phase 1 | NCT03099174 | May 2017 → May 2023 | breast neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02204072 | Nov 2014 → Oct 2019 | castration-resistant prostate carcinoma | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT02191891 | Oct 2014 → Apr 2018 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02145741 | Jun 2014 → Jul 2015 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02123823 | May 2014 → Nov 2016 | neoplasm | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT01403974 | Jul 2011 → Jul 2015 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01317420 | Apr 2011 → Feb 2016 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03659136 | Nov 2018 → Aug 2021 | breast cancer | Boehringer Ingelheim | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | xentuzumab | “xentuzumab (BI 836845) 1000 mg + everolimus 10 mg + exemestane 25 mg - Phase II” NCT02123823 ↗ |
| Known as | BI 836845 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02123823 ↗ |
| Action | Inhibit | “Xentuzumab, an insulin-like growth factor (IGF)-1/IGF-2-neutralising antibody, binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling.” PMID 32161368 ↗ Mar 20202“Insulin-like growth factor II inhibitor” CHEMBL4297850 ↗ “Insulin-like growth factor I inhibitor” CHEMBL4297850 ↗ |
| Modality | Monoclonal antibody | “Xentuzumab is a humanised monoclonal antibody” PMID 37308971 ↗ Jun 2023 |
| Route | Intravenous | “Patients received xentuzumab intravenously at a starting dose of 750 mg/wk.” PMID 34870878 ↗ Jan 2022 |
| Target | IGF1 | “Insulin-like growth factor I inhibitor” CHEMBL4297850 ↗ |
| Target | IGF2 | “Insulin-like growth factor II inhibitor” CHEMBL4297850 ↗ |
| Target | INSR | “neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A” NCT05110495 ↗ |